West Virginia University School of Medicine, Medicine - Nephrology, Box 9165, One Medical Center Drive, Morgantown, West Virginia 26506, USA.
Expert Opin Pharmacother. 2009 Jun;10(9):1509-14. doi: 10.1517/14656560902997982.
Since their inception nearly two decades ago, erythropoietin-stimulating agents (ESAs) have revolutionized the care of patients with renal anemia. Until recently, treatment options included the epoetins and darbepoetin alfa. As the use of these agents for chronic kidney disease (CKD) became widespread, the introduction of ESAs--touted for their longer-acting properties--was excitedly anticipated.
To review the option of methoxy polyethylene glycol-epoetin beta for ESA therapy in patients with renal anemia.
Peer-reviewed scientific literature, published abstracts and renal business journals were reviewed in the writing of this opinion.
RESULTS/CONCLUSION: Methoxy polyethylene glycol-epoetin beta (CERA) is an effective long-acting ESA approved for treatment of renal anemia and available for use outside of the United States. CERA corrects and maintains hemoglobin (Hb) levels in patients with CKD and its efficacy mirrors that of the epoetins and darbepoetin alfa. CERA holds promise for its safety record, administration requirements, and the potential impact on social and pharmacoeconomic barriers to treatment for patients with renal anemia.
自近二十年前问世以来，红细胞生成素刺激剂（ESAs）彻底改变了肾性贫血患者的治疗方式。直到最近，治疗方案还包括促红细胞生成素和达贝泊汀。随着这些药物在慢性肾脏病（CKD）中的广泛应用，具有长效特性的 ESAs 的引入备受期待。
综述用于肾性贫血治疗的聚乙二醇-红细胞生成素-β（methoxy polyethylene glycol-epoetin beta）作为 ESA 的选择方案。
在撰写本意见时，我们查阅了同行评议的科学文献、已发表的摘要和肾脏商业期刊。
结果/结论：聚乙二醇-红细胞生成素-β（CERA）是一种有效的长效 ESA，已获批用于治疗肾性贫血，且已在美国以外地区使用。CERA 可纠正和维持 CKD 患者的血红蛋白（Hb）水平，其疗效与促红细胞生成素和达贝泊汀相当。CERA 的安全性记录、给药要求以及对治疗肾性贫血患者的社会和药物经济学障碍的潜在影响，使其前景广阔。
